8-K

XOMA CORPORATION

Date: December 19, 2023

/s/ THOMAS BURNS

Thomas Burns

Senior Vice President, Finance and Chief Financial Officer

0001193125-23-298155.txt : 20231219 0001193125-23-298155.hdr.sgml : 20231219 20231219074033 ACCESSION NUMBER: 0001193125-23-298155 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 18 CONFORMED PERIOD OF REPORT: 20231215 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant ITEM INFORMATION: Unregistered Sales of Equity Securities ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20231219 DATE AS OF CHANGE: 20231219 FILER: COMPANY DATA: COMPANY CONFORMED NAME: XOMA Corp CENTRAL INDEX KEY: 0000791908 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 522154066 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39801 FILM NUMBER: 231495642 BUSINESS ADDRESS: STREET 1: 2200 POWELL STREET STREET 2: SUITE 310 CITY: EMERYVILLE STATE: CA ZIP: 94608 BUSINESS PHONE: 510-204-7239 MAIL ADDRESS: STREET 1: 2200 POWELL STREET STREET 2: SUITE 310 CITY: EMERYVILLE STATE: CA ZIP: 94608 FORMER COMPANY: FORMER CONFORMED NAME: XOMA LTD /DE/ DATE OF NAME CHANGE: 19990107 FORMER COMPANY: FORMER CONFORMED NAME: XOMA CORP /DE/ DATE OF NAME CHANGE: 19920703 8-K 1 d669381d8k.htm 8-K 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event Reported): December 15, 2023

XOMA CORPORATION

(Exact Name of Registrant as Specified in Charter)

DELAWARE

001-39801

52-2154066

(State or Other Jurisdiction

of Incorporation)

(Commission

File Number)

(I.R.S. Employer

Identification Number)

2200 Powell Street, Suite 310, Emeryville, California 94608

(Address of Principal Executive Offices) (Zip Code)

(510) 204-7200

(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class:	Trading symbol(s):	Name of each exchange on which registered:
Common Stock, $0.0075 par value	XOMA	The Nasdaq Global Market
8.625% Series A Cumulative Perpetual Preferred Stock, par value $0.05 per share	XOMAP	The Nasdaq Global Market
Depositary Shares (each representing 1/1000th interest in a share of 8.375% Series B Cumulative Perpetual Preferred Stock, par value $0.05 per share)	XOMAO	The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 1.01

Entry into a Material Definitive Agreement.

On December 15, 2023, XOMA Corporation (“XOMA”), through XRL 1 LLC, a newly formed, wholly-owned subsidiary (the “Subsidiary”), entered into a non-dilutive, non-recourse, royalty-backed loan for up to $140 million of capital (the “Royalty Financing”) with certain funds managed by the credit platform of Blue Owl Capital Inc. (collectively, “Blue Owl”). Pursuant to the Royalty Financing, XOMA, through another wholly-owned subsidiary, XOMA (US) LLC (“XOMA US”), contributed to the Subsidiary the following assets and rights related to VABYSMO^®: (i) XOMA US’ Assignment Agreement, dated October 6, 2021, with Affitech, F. Hoffmann-La Roche Ltd and Hoffman-La Roche Inc; (ii) certain commercial payments under XOMA US’ Commercial Payment Purchase Agreement (the “CPPA”), dated October 6, 2021, with Affitech Research AS (“Affitech”); (iii) any rights to erroneous payments in respect of such payments under the CPPA; and (iv) all proceeds of the foregoing. The VABYSMO-related assets and rights contributed to the Subsidiary are referred to herein as the “Contributed Assets.”

Simultaneously with the contribution and assignment of the Contributed Assets, the Subsidiary entered into a Loan Agreement (the “Loan Agreement”), dated December 15, 2023, with the lenders from time to time party thereto (the “Lenders”) and Blue Owl Capital Corporation, as administrative agent (the “Administrative Agent”), pursuant to which the lenders extended certain senior secured credit facilities to the Subsidiary (the “Loan”) in an aggregate principal amount of up to $140 million (the “Loan Amount”). The principal and interest of the Loan is to be paid from royalties received on worldwide net sales of VABYSMO (the “Commercial Payments”). The Subsidiary is obligated to make semi-annual interest payments at a fixed rate of 9.875% per annum until the royalty-backed loan is repaid, at which time the Commercial Payments would revert back to XOMA. The Loan matures on December 15, 2038, provided the Subsidiary may repay it in full at any time prior to December 15, 2038, subject to the terms of the Loan Agreement. The Loan includes (i) an initial term loan in an aggregate principal amount equal to $130 million and (ii) a delayed draw term loan in an aggregate principal amount of $10 million to be funded at the option of the Subsidiary upon receipt by the Lenders of payments of principal and interest from the proceeds of commercial payments related to VABYSMO in excess of an agreed upon amount on or prior to March 15, 2026. In exchange for the Contributed Assets, the Subsidiary will pay XOMA US up to $140 million, less certain lender expenses. The Subsidiary paid Blue Owl a market rate of original issue discount and during the term of the Loan, XOMA will also pay Blue Owl an administrative fee at a market rate. The royalty payment obligations under the Loan Agreement are limited to the Subsidiary, and Blue Owl has no recourse under the Loan Agreement against XOMA or XOMA US or any assets other than the Contributed Assets and XOMA US’ equity interest in the Subsidiary.

In connection with entering into the Loan Agreement, (i) the Subsidiary granted Blue Owl a first-priority perfected lien on, and security interest in, (a) the Commercial Payments and the proceeds thereof, in each case under the CPPA and (b) all other assets of the Subsidiary and (ii) XOMA US granted Blue Owl a first-priority perfected lien on, and security interest in 100% of the equity of the Subsidiary. XOMA also issued to Blue Owl warrants (the “Warrants”), to purchase (i) up to 40,000 shares of XOMA’s common stock, par value $0.0075 (“Common Stock”) at an exercise price of $35.00 per share, the form of which is attached to this Current Report on Form 8-K as Exhibit 4.1; (ii) up to 40,000 shares of Common Stock at an exercise price of $42.50 per share, the form of which is attached to this Current Report on Form 8-K as Exhibit 4.2; and (iii) up to 40,000 shares of Common Stock at an exercise price of $50.00 per share, the form of which is attached to this Current Report on Form 8-K as Exhibit 4.3. In the event of certain breaches of the Loan Agreement, the Administrative Agent may terminate the Loan Agreement and demand immediate payment of an amount equal to the Loan Amount plus Accreted Principal (as defined in the Loan Agreement), all interest thereon and all other obligations arising under or pursuant to the Loan Agreement and all other documents delivered in connection with such agreement. In the event that the Subsidiary fails to timely pay such amounts if and when due, then the Administrative Agent would have the right to foreclose on the pledged collateral.

The Loan Agreement contains other customary terms and conditions, including representations and warranties, as well as indemnification obligations in favor of Blue Owl. The above description of the Loan Agreement is a summary of the material terms and does not purport to be complete; the summary is qualified in its entirety by reference to the Loan Agreement, a copy of which will be filed as an exhibit to XOMA’s Annual Report on Form 10-K to be filed with the Securities and Exchange Commission for the fiscal year ending December 31, 2023.

The above descriptions of the Warrants are summaries of the material terms and do not purport to be complete; the summaries are qualified in its entirety by reference to the respective forms of Warrant attached to this Current Report on Form 8-K as Exhibits 4.1, 4.2 and 4.3 and incorporated herein by reference.

Item 2.03

Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

The information in Item 1.01 above relating to the Subsidiary’s obligations to make payments with respect to the Loan is incorporated by reference into this Item 2.03.

Item 3.02

Unregistered Sales of Equity Securities.

The information in Item 1.01 above relating to the issuance of the Warrant is incorporated by reference into this Item 3.02.

The Warrants described in Item 1.01 above were offered and sold in reliance upon the exemption from registration provided by Section 4(a)(2) under the Securities Act of 1933, as amended.

Item 9.01.

Financial Statements and Exhibits.

(d) Exhibits.


Exhibit No.		Description

4.1		Form of Warrant (December 2023) ($35.00 Exercise Price)

4.2		Form of Warrant (December 2023) ($42.50 Exercise Price)

4.3		Form of Warrant (December 2023) ($50.00 Exercise Price)

99.1		Press release, dated December 19, 2023.

104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

EX-4.1 2 d669381dex41.htm EX-4.1 EX-4.1

Exhibit 4.1

THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AS SET FORTH IN SECTIONS 5.3 AND 5.4 BELOW, MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND LAWS OR, IN THE OPINION OF LEGAL COUNSEL IN FORM AND SUBSTANCE SATISFACTORY TO THE ISSUER, SUCH OFFER, SALE, PLEDGE OR OTHER TRANSFER IS EXEMPT FROM SUCH REGISTRATION.

WARRANT TO PURCHASE STOCK

Warrant No.: [●]

Company: XOMA Corporation, a Delaware corporation

Number of Shares: [●], subject to adjustment

Type/Series of Stock: Common Stock, $0.0075 par value per share

Warrant Price: $35.00 per share, subject to adjustment

Issue Date: December 15, 2023

Expiration Date: December 15, 2033 See also Section 5.1(b).

Credit Facility: This Warrant to Purchase Stock (“Warrant”) is issued in connection with that certain Loan Agreement, of even date herewith, among XRL 1 LLC, as borrower, the lenders from time to time party thereto and Blue Owl Capital Corporation, as administrative agent (as may be further amended and/or modified and in effect from time to time, the “Loan Agreement”; capitalized terms used herein but not defined herein shall have the meaning set forth in the Loan Agreement).

THIS WARRANT CERTIFIES THAT, for good and valuable consideration, [BLUE OWL CAPITAL CORPORATION] (together with any successor or permitted assignee or transferee of this Warrant or of any shares issued upon exercise hereof, “Holder”) is entitled to purchase up to such number of fully paid and non-assessable shares (the “Shares”) of the above-stated Type/Series of Stock (the “Class”) of the above-named company (the “Company”), at the above-stated Warrant Price, all as set forth above and subject to the provisions and upon the terms and conditions set forth in this Warrant.

SECTION 1. EXERCISE.

1.1 Method of Exercise. Holder may at any time and from time to time exercise this Warrant, in whole or in part, by delivering to the Company the original of this Warrant together with a duly executed Notice of Exercise in substantially the form attached hereto as Appendix 1 and, unless Holder is exercising this Warrant pursuant to a cashless exercise set forth in Section 1.2, a check, wire transfer of same-day funds (to an account designated by the Company), or other form of payment acceptable to the Company for the aggregate Warrant Price for the Shares being purchased.

1.2 Cashless Exercise. On any exercise of this Warrant, in lieu of payment of the aggregate Warrant Price in the manner as specified in Section 1.1 above, but otherwise in accordance with the requirements of Section 1.1, Holder may elect to receive Shares equal to the value of this Warrant, or portion hereof as to which this Warrant is being exercised. Thereupon, the Company shall issue to the Holder such number of fully paid and non-assessable Shares as are computed using the following formula:

X = Y(A-B)/A

where:

X = the number of Shares to be issued to the Holder;

Y = the number of Shares with respect to which this Warrant is being exercised (inclusive of the Shares surrendered to the Company in payment of the aggregate Warrant Price);

A = the Fair Market Value (as determined pursuant to Section 1.3 below) of one Share; and

B = the Warrant Price.

1.3 Fair Market Value. If shares of the Class are then traded or quoted on a nationally recognized securities exchange, inter-dealer quotation system or over-the-counter market (a “Trading Market”), the fair market value of a Share shall be the closing price or last sale price of a share of the Class reported for the Business Day immediately before the date on which Holder delivers this Warrant together with its Notice of Exercise to the Company. If shares of the Class are not then traded in a Trading Market, the Board of Directors of the Company shall determine the fair market value of a Share in its reasonable good faith judgment.

1.4 Delivery of Certificate and New Warrant. Within a reasonable time after Holder exercises this Warrant in the manner set forth in Section 1.1 or 1.2 above, the Company shall deliver to Holder a certificate representing the Shares issued to Holder upon such exercise (which certificate may be in the form of an electronic certificate or DTC entry, to the extent used by the Company at the time of such exercise) and, if this Warrant has not been fully exercised and has not expired, a new warrant of like tenor representing the Shares not so acquired.

1.5 Replacement of Warrant. On receipt of evidence reasonably satisfactory to the Company of the loss, theft, destruction or mutilation of this Warrant and, in the case of loss, theft or destruction, on delivery of an indemnity agreement reasonably satisfactory in form, substance and amount to the Company or, in the case of mutilation, on surrender of this Warrant to the Company for cancellation, the Company shall, within a reasonable time, execute and deliver to Holder, in lieu of this Warrant, a new warrant of like tenor and amount.

1.6 Treatment of Warrant Upon Acquisition of Company.

(a) Acquisition. For the purpose of this Warrant, “Acquisition” means any transaction or series of related transactions involving: (i) the sale, lease, exclusive license, or other disposition of all or substantially all of the assets of the Company; (ii) any merger or consolidation of the Company into or with another person or entity (other than a merger or consolidation effected exclusively to change the Company’s domicile), or any other corporate reorganization, in which the stockholders of the Company in their capacity as such immediately prior to such merger, consolidation or reorganization, own less than a majority of the Company’s (or the surviving or successor entity’s) outstanding voting power immediately after such merger, consolidation or reorganization (or, if such Company stockholders beneficially own a majority of the outstanding voting power of the surviving or successor entity as of immediately after such merger, consolidation or reorganization, such surviving or successor entity is not the Company); or (iii) any sale or other transfer by the stockholders of the Company of shares representing at least a majority of the Company’s then-total outstanding combined voting power.

(b) Treatment of Warrant at Acquisition. In the event of an Acquisition in which the consideration to be received by the Company’s stockholders consists solely of cash, solely of Marketable Securities or a combination of cash and Marketable Securities (a “Cash/Public Acquisition”), and the fair market value of one Share as determined in accordance with Section 1.3 above would be greater than the Warrant Price in effect on such date immediately prior to such Cash/Public Acquisition, and Holder has not exercised this Warrant pursuant to Section 1.1 above as to all Shares, then this Warrant shall automatically be deemed to be Cashless Exercised pursuant to Section 1.2 above as to all Shares effective immediately prior to and contingent upon the consummation of a Cash/Public Acquisition. In connection with such Cashless Exercise, Holder shall be deemed to have restated each of the representations and warranties in Section 4 of the Warrant as of the date thereof and the Company shall promptly notify the Holder of the number of Shares (or such other securities) issued upon exercise. In the event of a Cash/Public Acquisition where the fair market value of one Share as determined in accordance with Section 1.3 above would be less than the Warrant Price in effect immediately prior to such Cash/Public Acquisition, then this Warrant will expire immediately prior to the consummation of such Cash/Public Acquisition.

(c) Upon the closing of any Acquisition other than a Cash/Public Acquisition, the acquiring, surviving or successor entity shall assume the obligations of this Warrant, and this Warrant shall thereafter be exercisable for the same securities and/or other property as would have been paid for the Shares issuable upon exercise of the unexercised portion of this Warrant as if such Shares were outstanding on and as of the closing of such Acquisition, subject to further adjustment from time to time in accordance with the provisions of this Warrant.

(d) As used in this Warrant, “Marketable Securities” means securities meeting all of the following requirements: (i) the issuer thereof is then subject to the reporting requirements of Section 13 or Section 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and is then current in its filing of all required reports and other information under the Act and the Exchange Act; (ii) the class and series of shares or other security of the issuer that would be received by Holder in connection with the Acquisition were Holder to exercise this Warrant on or prior to the closing thereof is then traded in a Trading Market, and (iii) following the closing of such Acquisition, Holder would not be restricted from publicly re-selling all of the issuer’s shares and/or other securities that would be received by Holder in such Acquisition were Holder to exercise this Warrant in full on or prior to the closing of such Acquisition, except to the extent that any such restriction (x) arises solely under federal or state securities laws, rules or regulations, and (y) does not extend beyond six (6) months from the closing of such Acquisition.

SECTION 2. ADJUSTMENTS TO THE SHARES AND WARRANT PRICE.

2.1 Stock Dividends, Splits, Etc. If the Company declares or pays a dividend or distribution on the outstanding shares of the Class payable in additional shares of the Class or other securities or property (other than cash), then upon exercise of this Warrant, for each Share acquired, Holder shall receive, without additional cost to Holder, the total number and kind of securities and property which Holder would have received had Holder owned the Shares of record as of the date the dividend or distribution occurred. If the Company subdivides the outstanding shares of the Class by reclassification or otherwise into a greater number of shares, the number of Shares purchasable hereunder shall be proportionately increased and the Warrant Price shall be proportionately decreased. If the outstanding shares of the Class are combined or consolidated, by reclassification or otherwise, into a lesser number of shares, the Warrant Price shall be proportionately increased and the number of Shares shall be proportionately decreased.

2.2 Reclassification, Exchange, Combinations or Substitution. Upon any event whereby all of the outstanding shares of the Class are reclassified, exchanged, combined, substituted, or replaced for, into, with or by Company securities of a different class and/or series, then from and after the consummation of such event, this Warrant will be exercisable for the number, class and series of Company securities that Holder would have received had the Shares been outstanding on and as of the consummation of such event, and subject to further adjustment thereafter from time to time in accordance with the provisions of this Warrant. The provisions of this Section 2.2 shall similarly apply to successive reclassifications, exchanges, combinations, substitutions, replacements or other similar events.

2.3 No Fractional Share. No fractional Share shall be issuable upon exercise of this Warrant and the number of Shares to be issued shall be rounded down to the nearest whole Share. If a fractional Share interest arises upon any exercise of the Warrant, the Company shall eliminate such fractional Share interest by paying Holder in cash the amount computed by multiplying the fractional interest by (i) the fair market value (as determined in accordance with Section 1.3 above) of a full Share, less (ii) the then-effective Warrant Price.

2.4 Notice/Certificate as to Adjustments. Upon each adjustment of the Warrant Price, Class and/or number of Shares, the Company, at the Company’s expense, shall notify Holder in writing within a reasonable time setting forth the adjustments to the Warrant Price, Class and/or number of Shares and facts upon which such adjustment is based. The Company shall, upon written request from Holder, furnish Holder with a certificate of its Chief Financial Officer, including computations of such adjustment and the Warrant Price, Class and number of Shares in effect upon the date of such adjustment.

2.5 Tax Treatment as to Adjustments. The Company acknowledges its obligations to file and/or publicly post (as applicable) an IRS Form 8937 (or similar tax form) if an adjustment (or lack thereof) to the Warrant entitlement results in a distribution under Section 305(c) of the Internal Revenue Code of 1986, as amended, and agrees to notify Holder on a timely basis in the event of such an adjustment (or lack thereof) and, in the case of any required IRS Form 8937 filing, consider, in good faith, any timely received, reasonable written comments of Holder in preparing such IRS Form 8937. For the avoidance of doubt, if there is more than one permissible method to determine the amount of the constructive dividend for tax purposes, unless Holder gives notice otherwise, the Company agrees to select the method that results in the lowest constructive dividend amount as long as such method is at a “more likely than not” level of comfort.

SECTION 3. REPRESENTATIONS AND COVENANTS OF THE COMPANY.

3.1 Representations and Warranties. The Company represents and warrants to, and agrees with, the Holder as follows:

(a) All Shares which may be issued upon the exercise of this Warrant shall, upon issuance, be duly authorized, validly issued, fully paid and non-assessable, and free of any liens and encumbrances except for restrictions on transfer provided for herein or under applicable federal and state securities laws.

(b) The Company covenants that it shall at all times cause to be reserved and kept available out of its authorized and unissued capital stock such number of shares of the Class and other securities as will be sufficient to permit the exercise in full of this Warrant.

3.2 Notice of Certain Events. If the Company proposes at any time to:

(a) declare any dividend or distribution upon the outstanding shares of the Class, whether in cash, property, stock, or other securities and whether or not a regular cash dividend;

(b) offer for subscription or sale pro rata to the holders of the outstanding shares of the Class any additional shares of any class or series of the Company’s stock (other than pursuant to contractual pre-emptive rights);

(c) effect any reclassification, exchange, combination, substitution, reorganization or recapitalization of the outstanding shares of the Class; or

(d) effect an Acquisition or to liquidate, dissolve or wind up;

then, in connection with each such event, the Company shall give Holder notice thereof at the same time and in the same manner as given to holders of the outstanding shares of the Class.

3.3 Direction to Transfer Agent. Upon each exercise of the Warrant (in whole or in part), the Company shall promptly deliver irrevocable authorization and direction to its transfer agent to issue book-entry statements representing the Shares.

SECTION 4. REPRESENTATIONS AND WARRANTIES OF THE HOLDER.

The Holder represents and warrants to the Company as follows:

4.1 Purchase for Own Account. This Warrant and the Shares to be acquired upon exercise of this Warrant by Holder are being acquired for investment for Holder’s account, not as a nominee or agent, and not with a view to the public resale or distribution within the meaning of the Act. Holder also represents that it has not been formed for the specific purpose of acquiring this Warrant or the Shares.

4.2 Disclosure of Information. Holder is aware of the Company’s business affairs and financial condition and has received or has had full access to all the information it considers necessary or appropriate to make an informed investment decision with respect to the acquisition of this Warrant and its underlying securities. Holder further has had an opportunity to ask questions and receive answers from the Company regarding the terms and conditions of the offering of this Warrant and its underlying securities and to obtain additional information (to the extent the Company possessed such information or could acquire it without unreasonable effort or expense) necessary to verify any information furnished to Holder or to which Holder has access.

4.3 Investment Experience. Holder understands that the purchase of this Warrant and its underlying securities involves substantial risk. Holder has experience as an investor in securities of companies in the development stage and acknowledges that Holder can bear the economic risk of such Holder’s investment in this Warrant and its underlying securities and has such knowledge and experience in financial or business matters that Holder is capable of evaluating the merits and risks of its investment in this Warrant and its underlying securities and/or has a preexisting personal or business relationship with the Company and certain of its officers, directors or controlling persons of a nature and duration that enables Holder to be aware of the character, business acumen and financial circumstances of such persons.

4.4 Accredited Investor Status. Holder is an “accredited investor” within the meaning of Regulation D promulgated under the Act.

4.5 The Act. Holder understands that this Warrant and the Shares issuable upon exercise hereof have not been registered under the Act in reliance upon a specific exemption therefrom, which exemption depends upon, among other things, the bona fide nature of the Holder’s investment intent as expressed herein. Holder understands that this Warrant and the Shares issued upon any exercise hereof must be held indefinitely unless subsequently registered under the Act and qualified under applicable state securities laws, or unless exemption from such registration and qualification are otherwise available. Holder is aware of the provisions of Rule 144 promulgated under the Act.

4.6 No Shareholder Rights. Without limiting any provision of this Warrant, Holder agrees that as a Holder of this Warrant it will not have any rights (including, but not limited to, voting rights) as a shareholder of the Company with respect to the Shares issuable hereunder unless and until the exercise of this Warrant and then only with respect to the Shares issued on such exercise.

SECTION 5. MISCELLANEOUS.

5.1 Term; Automatic Cashless Exercise Upon Expiration.

(a) Term. Subject to the provisions of Section 1.6 above, this Warrant is exercisable in whole or in part at any time and from time to time on or before 6:00 PM, Pacific time, on the Expiration Date and shall be void thereafter.

(b) Automatic Cashless Exercise upon Expiration. In the event that, upon the Expiration Date, the fair market value of one Share as determined in accordance with Section 1.3 above is greater than the Warrant Price in effect on such date, then this Warrant shall automatically be deemed on and as of such date to be exercised pursuant to Section 1.2 above as to all Shares for which it shall not previously have been exercised, and the Company shall, within a reasonable time, deliver a certificate representing the Shares issued upon such exercise to Holder (which certificate may be in the form of an electronic certificate or DTC entry, to the extent used by the Company at the time of such exercise).

5.2 Legends. Each certificate evidencing Shares shall be imprinted with a legend in substantially the following form:

THE SHARES EVIDENCED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AS SET FORTH IN THAT CERTAIN WARRANT TO PURCHASE STOCK ISSUED BY THE ISSUER TO [BLUE OWL CAPITAL CORPORATION] DATED DECEMBER 15, 2023, MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND LAWS OR, IN THE OPINION OF LEGAL COUNSEL IN FORM AND SUBSTANCE SATISFACTORY TO THE ISSUER, SUCH OFFER, SALE, PLEDGE OR OTHER TRANSFER IS EXEMPT FROM SUCH REGISTRATION.

5.3 Compliance with Securities Laws on Transfer. This Warrant and the Shares issued upon exercise of this Warrant may not be transferred or assigned in whole or in part except in compliance with applicable federal and state securities laws by the transferor and the transferee (including, without limitation, the delivery of investment representation letters and legal opinions reasonably satisfactory to the Company, as reasonably requested by the Company). The Company shall not require Holder to provide an opinion of counsel if the transfer is to an affiliate of

Holder, provided that any such transferee is an “accredited investor” as defined in Regulation D promulgated under the Act. Additionally, the Company shall also not require an opinion of counsel if there is no material question as to the availability of Rule 144 promulgated under the Act. For purposes of an affiliate transfer contemplated herein, the Company hereby approves each and every registered investment company, private equity fund, venture capital fund, private or similar collective investment vehicle now or hereafter existing that is controlled by one or more affiliated general partners, managing members or investment advisers of, or shares an affiliated management company or investment adviser with, the Holder as an “affiliate” of the Holder.

5.4 Transfer Procedure. Subject to the provisions of Section 5.3 and upon providing the Company with written notice, [Blue Owl Capital Corporation] and any subsequent Holder may transfer all or part of this Warrant to any transferee, provided, however, in connection with any such transfer, [Blue Owl Capital Corporation] or any subsequent Holder will give the Company notice of the portion of the Warrant being transferred with the name, address and taxpayer identification number of the transferee and Holder will surrender this Warrant to the Company for reissuance to the transferee(s) (and Holder if applicable); and provided further, that any subsequent transferee of this Warrant or of any portion hereof shall agree in writing with the Company to be bound by all of the terms and conditions of this Warrant.

5.5 Notices. All notices and other communications hereunder from the Company to the Holder, or vice versa, shall be deemed delivered and effective (i) when given personally, (ii) on the third (3rd) Business Day after being mailed by first-class registered or certified mail, postage prepaid, (iii) upon actual receipt if given by electronic mail and such receipt is confirmed in writing by the recipient, or (iv) on the first Business Day following delivery to a reliable overnight courier service, courier fee prepaid, in any case at such address as may have been furnished to the Company or Holder, as the case may be, in writing by the Company or such Holder from time to time in accordance with the provisions of this Section 5.5. All notices to Holder shall be addressed as follows until the Company receives notice of a change of address in connection with a transfer or otherwise:

[Holder]

c/o Blue Owl Capital Corporation

399 Park Avenue, 37th Floor

New York, NY 10022

Telephone:

Email address:

with a copy (which shall not constitute notice) to:

Cooley LLP

Attn: Michael Tollini

1299 Pennsylvania Avenue, NW, Suite 700

Washington, DC 20004-2400

Email: mtollini@cooley.com

Notice to the Company shall be addressed as follows until Holder receives notice of a change in address:

XOMA Corporation

Attn: Chief Financial Officer

2200 Powell Street, Suite 310

Emeryville, CA 94608

Telephone:

Email:

With a copy (which shall not constitute notice) to:

Gibson, Dunn & Crutcher LLP

Attn: Ryan Murr and Branden Berns

555 Mission Street, Suite #3000

San Francisco, CA 94105

Telephone: (415) 393-8373; (415) 393-4631

Email: rmurr@gibsondunn.com; bberns@gibsondunn.com

5.6 Waiver. This Warrant and any term hereof may be changed, waived, discharged or terminated (either generally or in a particular instance and either retroactively or prospectively) only by an instrument in writing signed by the party against which enforcement of such change, waiver, discharge or termination is sought.

5.7 Attorneys’ Fees. In the event of any dispute between the parties concerning the terms and provisions of this Warrant, the party prevailing in such dispute shall be entitled to collect from the other party all costs incurred in such dispute, including reasonable attorneys’ fees.

5.8 Counterparts; Facsimile/Electronic Signatures. This Warrant may be executed in counterparts, all of which together shall constitute one and the same agreement. Any signature page delivered electronically or by facsimile shall be binding to the same extent as an original signature page with regards to any agreement subject to the terms hereof or any amendment thereto.

5.9 Governing Law. This Warrant shall be governed by and construed in accordance with the laws of the State of New York, without giving effect to its principles regarding conflicts of law.

5.10 Headings. The headings in this Warrant are for purposes of reference only and shall not limit or otherwise affect the meaning of any provision of this Warrant.

5.11 Business Days. “Business Day” is any day that is not a Saturday, Sunday or other day on which commercial banks in New York City are authorized or required by Applicable Law to remain closed.

[Remainder of page left blank intentionally]

[Signature page follows]

IN WITNESS WHEREOF, the parties have caused this Warrant to Purchase Stock to be executed by their duly authorized representatives effective as of the Issue Date written above.


“COMPANY”

XOMA CORPORATION

By:
Name:		Thomas Burns
Title:		Chief Financial Officer

“HOLDER”

[BLUE OWL CAPITAL CORPORATION]

By:
Name:
Title:

APPENDIX 1

NOTICE OF EXERCISE

1. The undersigned Holder hereby exercises its right to purchase ___________ shares of the Common/Series ______ Preferred [circle one] Stock of __________________ (the “Company”) in accordance with the attached Warrant To Purchase Stock, and tenders payment of the aggregate Warrant Price for such shares as follows:

[ ] check in the amount of $________ payable to order of the Company enclosed herewith

[ ] Wire transfer of immediately available funds to the Company’s account

[ ] Cashless Exercise pursuant to Section 1.2 of the Warrant

[ ] Other [Describe] __________________________________________

2. Please issue a certificate or certificates representing the Shares in the name specified below:

__________________________________________

Holder’s Name

__________________________________________

(Address)

3. By its execution below and for the benefit of the Company, Holder hereby restates each of the representations and warranties in Section 4 of the Warrant to Purchase Stock as of the date hereof.

HOLDER:

_______________________________

By:_________________________________

Name:________________________________

Title:_________________________________

(Date):_______________________________

Appendix 1

Schedule 1

Representations and Warranties of the Company

(a) The Company is a corporation duly organized, validly existing and in good standing under the laws of the state of Delaware and has all powers and authority, and all licenses, permits, franchises, authorizations, consents and approvals of all Governmental Authorities, required to own its property and conduct its business as now conducted. The Company is duly qualified to transact business and is in good standing in every jurisdiction in which such qualification or good standing is required by applicable law (except where the failure to be so qualified or in good standing would not result in, and could not reasonably be expected to have resulted in a Material Adverse Effect). As used herein: (i) “Material Adverse Effect” means (a) an Insolvency Event, (b) a material adverse change in the business, operations, properties, results of operations or financial condition of the Company, taken as a whole; (c) a material adverse effect on the validity or enforceability of the Transaction Documents taken as a whole or any material provision hereof or thereof; (d) a material adverse effect on the ability of any Transaction Party to consummate the transactions contemplated by the Transaction Documents, or on the ability of any Transaction Party to perform its obligations under the Transaction Documents to which it is a party; or (e) a material adverse effect on the rights or remedies of the Holder, the Administrative Agent or the Lenders under any of the Transaction Documents, taken as a whole and (ii) “Transaction Documents” mean the Loan Documents together with the Warrant.

(b) None of the execution and delivery by the Company of any of the Transaction Documents to which Parent is party, the performance by the Company of the obligations contemplated hereby or thereby or the consummation of the transactions contemplated hereby or thereby will: (i) contravene, conflict with, result in a breach, violation, cancellation or termination of, constitute a default (with or without notice or lapse of time, or both) under, require prepayment under, give any Person the right to exercise any remedy (including termination, cancellation or acceleration) or obtain any additional rights under, or accelerate the maturity or performance of or payment under, in any respect, (A) any Applicable Law or any judgment, order, writ, decree, permit or license of any Governmental Authority to which the Company or any of its Subsidiaries or any of their respective assets or properties may be subject or bound, (B) any term or provision of any contract, agreement, indenture, lease, license, deed, commitment, obligation or instrument to which the Company or any of its Subsidiaries is a party or by which the Company or any of its Subsidiaries or any of their respective assets or properties is bound or committed or (C) any term or provision of any of the organizational documents of the Company or any of its Subsidiaries, except in the case of clause (A) or (B) where any such event would not result in a Material Adverse Effect.

(c) The Company has all powers and authority to execute and deliver, and perform its obligations under, the Transaction Documents to which it is party and to consummate the transactions contemplated hereby and thereby. The execution and delivery of each of the Transaction Documents to which the Company is party and the performance by the Company of its obligations hereunder and thereunder have been duly authorized by the Company. Each of the Transaction Documents to which the Company is party has been duly executed and delivered by the Company. Each of the Transaction Documents to which the Company is party constitutes the legal, valid and binding obligation of the Company, enforceable against the Company in accordance with its respective terms, subject to applicable bankruptcy, insolvency, reorganization, moratorium or similar Applicable Laws affecting creditors’ rights generally, general equitable principles and principles of public policy.

(d) The execution and delivery by the Company of the Transaction Documents to which the Company is party, the performance by the Company of its obligations hereunder and thereunder and the consummation of any of the transactions contemplated hereunder and thereunder do not require any consent, approval, license, order, authorization or declaration from, notice to, action or registration by or filing with any Governmental Authority or any other Person, except for the filing of (i) any applicable notices under securities laws and (ii) those previously obtained and in full force and effect.

(e) There is no action, suit, arbitration proceeding, claim, citation, summons, subpoena, investigation or other proceeding (whether civil, criminal, administrative, regulatory, investigative or informal, and including by or before a Governmental Authority) pending or, to the knowledge of the Company, threatened in writing (or, in the case of a threat by a Governmental Authority, threatened orally or in writing) by or against the Company or any of its Subsidiaries, at law or in equity, that (i) if adversely determined, would result in a Material Adverse Effect or (ii) challenges or seeks to prevent or delay the consummation of any of the transactions contemplated by any of the Transaction Documents to which the Company is party.

Schedule 1.1

(f) Upon consummation of the transactions contemplated by the Transaction Documents and the application of the proceeds of the Term Loan to be made on the Closing Date, (a) the present fair saleable value of the properties and assets of the Company will be greater than the sum of its debts, liabilities and other obligations, including contingent liabilities, (b) the present fair saleable value of the properties and assets of the Company will not be less than the amount that would be required to pay its probable liabilities on its existing debts, liabilities and other obligations, including contingent liabilities, as they become absolute and matured, (c) the Company will be generally able to realize upon its assets and pay its debts, liabilities and other obligations, including contingent obligations, as they become absolute and matured, (d) the Company will not have unreasonably small capital with which to engage in its business as now conducted, (e) the Company has not incurred, will not incur and does not have any present plans or intentions to incur debts or other obligations or liabilities beyond its ability to pay such debts or other obligations or liabilities as they become absolute and matured, (f) the Company will not have become subject to any Insolvency Event and (g) the Company will not have been rendered insolvent within the meaning of any Applicable Law. No step has been taken by the Company or, to its knowledge, any other Person to make the Company subject to an Insolvency Event.

(g) No Default or Event of Default has occurred and is continuing, and no such event will occur upon the making of the Term Loan to be made on the applicable Credit Date.

(h) The Company has timely filed (or caused to be filed) all Tax returns and reports required by Applicable Law to have been filed by it and has paid all Taxes required to be paid by it (including in its capacity as a withholding agent), except any such Taxes that are being contested in good faith by appropriate proceedings and for which adequate reserves in accordance with GAAP have been set aside on its books or where any such failure to file or pay would not result, individually or in the aggregate, in a Material Adverse Effect.

(i) None of the Company or any of its Subsidiaries (a) has violated or is in violation of, is under investigation with respect to or has been threatened to be charged with or been given notice of any violation of, any Applicable Law or any judgment, order, writ, decree, injunction, stipulation, consent order, permit or license granted, issued or entered by any Governmental Authority or (b) is subject to any judgment, order, writ, decree, injunction, stipulation, consent order, permit or license granted, issued or entered by any Governmental Authority, in each case, that would result in a Material Adverse Effect. Each of the Company and any Subsidiary of the Company is in compliance with the requirements of all Applicable Laws, a breach of any of which would result in a Material Adverse Effect.

(j) Neither the Company nor any of its Subsidiaries is an “investment company”, or a company “controlled” by an “investment company”, within the meaning of the Investment Company Act of 1940.

(k) The Financial Statements are complete and accurate in all material respects, were prepared in conformity with GAAP applied on a consistent basis during the periods involved (except as may be indicated in the notes thereto) and present fairly in all material respects, in accordance with applicable requirements of GAAP, the consolidated financial position and the consolidated financial results of the operations of the Company and its Subsidiaries as of the dates and for the periods covered thereby and the consolidated statements of cash flows of the Company and its Subsidiaries for the periods presented therein. Since December 31, 2021, there has been no Material Adverse Effect. The Company and its Subsidiaries have no Indebtedness (or other liabilities) other than (i) identified in the Financial Statements or (ii) incurred by the Company or its Subsidiaries in the ordinary course of business since December 31, 2021.

(l) Neither the Company nor any of the directors, officers, employees or, to the Company’s knowledge, agents of the Company have, directly or indirectly, made, offered, promised or authorized any payment or gift of any money or anything of value to or for the benefit of any “foreign official” (as such term is defined in the FCPA), foreign political party or official thereof or candidate for foreign political office for the purpose of (i) influencing any official act or decision of such official, party or candidate, including inducing such official, party or candidate to do or omit to do any act in violation of such person’s lawful duty; (ii) inducing such official, party or candidate to use such person’s influence to affect any act or decision of a foreign governmental authority, or (iii) otherwise securing any

Schedule 1.1

improper advantage, in the case of (i), (ii) and (iii) above in order to assist the Company or any of its affiliates in obtaining or retaining business for or with, or directing business to, any person. Neither the Company nor any of its directors, officers, employees or, to the Company’s knowledge, agents have made or authorized any bribe, rebate, payoff, influence payment, kickback or other unlawful payment of funds or received or retained any funds in violation of any law, rule or regulation. Neither the Company nor, to the Company’s knowledge, any of its officers, directors or employees are the subject of any allegation, voluntary disclosure, investigation, prosecution or other enforcement action related to the FCPA or any other anti-corruption law.

(m) The Company, its Subsidiaries, their respective directors, officers, employees, and, to the knowledge of the foregoing, agents of the same are and for the past five years have been in compliance with applicable laws and regulations pertaining to export controls and trade and economic sanctions, including those administered and enforced by the U.S. Department of Commerce, U.S. Department of State, and U.S. Department of the Treasury (collectively, “Trade Control Laws”). None of the Company, its Subsidiaries, or their respective directors, officers, employees, or, to the Company’s knowledge, the Company’s or it Subsidiaries’ agents is: (i) organized under the laws of, ordinarily resident in, or located in a country or territory that is the subject of comprehensive Sanctions (which as of the date of this Agreement comprise Cuba, Iran, North Korea, Syria, and the Crimea, Donetsk People’s Republic, and Luhansk People’s Republic regions of Ukraine (each a “Sanctioned Country”)); (ii) 50% or more owned or controlled by the government of a Sanctioned Country; or (iii) (A) designated on a sanctioned parties list administered by the United States or other applicable government authority, including, without limitation, the U.S. Department of the Treasury’s Office of Foreign Assets Control’s Specially Designated Nationals and Blocked Persons List or Foreign Sanctions Evaders List ( “Listed Parties”); or (B) 50% or more owned or, where relevant under applicable Trade Control Laws, controlled, individually or in the aggregate, by one or more Listed Parties (collectively, “Sanctioned Parties”). The Company has obtained all export licenses and other approvals, and timely made all filings, in each case to the extent required pursuant to applicable Trade Control Laws. There are no pending or, to the Company’s knowledge, threatened claims or investigations against the Company with respect to Trade Control Laws, and no actions, conditions, or circumstances pertaining to the Company’s activities that would reasonably be expected to give rise to any material future claims. The Company shall not directly or indirectly use the proceeds of this transaction or lend, contribute, or otherwise make available such proceeds to any Sanctioned Country or Sanctioned Party, or in any manner that will result in a violation of Trade Control Laws.

(n) The underlying assets of the Company and its Subsidiaries do not constitute Plan Assets. The execution, delivery and performance of this Agreement and the other Loan Documents do not and will not constitute a non-exempt prohibited transaction under Section 406 of ERISA or Section 4975 of the Internal Revenue Code, or similar laws.

(o) At no time in the past six years has the Company, its Subsidiaries or any ERISA Affiliates maintained or contributed to, been required to maintain or contribute to, or otherwise had any liability (contingent or otherwise) with respect to any Employee Benefit Plan subject to Title IV of ERISA, Section 302 of ERISA or the minimum funding requirements of Section 412 of the Code, or a “multiemployer plan” (as defined in Section 3(37) of ERISA). As used herein, “ERISA Affiliate” means, as applied to any Person, (a) any corporation which is a member of a controlled group of corporations within the meaning of Section 414(b) of the Internal Revenue Code of which that Person is a member; (b) any trade or business (whether or not incorporated) which is a member of a group of trades or businesses under common control within the meaning of Section 414(c) of the Internal Revenue Code of which that Person is a member; and (c) any member of an affiliated service group within the meaning of Section 414(m) or (o) of the Internal Revenue Code of which that Person, any corporation described in clause (a) above or any trade or business described in clause (b) above is a member. Any former ERISA Affiliate of Borrower or any of its Subsidiaries shall continue to be considered an ERISA Affiliate of Borrower or any such Subsidiary within the meaning of this definition with respect to the period such entity was an ERISA Affiliate of Borrower or such Subsidiary and with respect to liabilities arising after such period for which Borrower or such Subsidiary could be liable under the Internal Revenue Code or ERISA.

(p) All written information heretofore or herein supplied by the Company to the Holder, Administrative Agent or any Lender is accurate and complete in all material respects. There is no fact or circumstance known to the Company that could reasonably be expected to have a Material Adverse Effect that has not been expressly disclosed to the Holder, the Administrative Agent and each Lender or in required reports and other information filed with the SEC under the Act and the Exchange Act (to the extent publicly available).

Schedule 1.1

EX-4.2 3 d669381dex42.htm EX-4.2 EX-4.2

Exhibit 4.2

WARRANT TO PURCHASE STOCK

Warrant No.: [●]

Company: XOMA Corporation, a Delaware corporation

Number of Shares: [●], subject to adjustment

Type/Series of Stock: Common Stock, $0.0075 par value per share

Warrant Price: $42.50 per share, subject to adjustment

Issue Date: December 15, 2023

Expiration Date: December 15, 2033 See also Section 5.1(b).

SECTION 1. EXERCISE.

X = Y(A-B)/A

where:

X = the number of Shares to be issued to the Holder;

Y = the number of Shares with respect to which this Warrant is being exercised (inclusive of the Shares surrendered to the Company in payment of the aggregate Warrant Price);

A = the Fair Market Value (as determined pursuant to Section 1.3 below) of one Share; and

B = the Warrant Price.

1.6 Treatment of Warrant Upon Acquisition of Company.

SECTION 2. ADJUSTMENTS TO THE SHARES AND WARRANT PRICE.

SECTION 3. REPRESENTATIONS AND COVENANTS OF THE COMPANY.

3.1 Representations and Warranties. The Company represents and warrants to, and agrees with, the Holder as follows:

3.2 Notice of Certain Events. If the Company proposes at any time to:

(a) declare any dividend or distribution upon the outstanding shares of the Class, whether in cash, property, stock, or other securities and whether or not a regular cash dividend;

(c) effect any reclassification, exchange, combination, substitution, reorganization or recapitalization of the outstanding shares of the Class; or

(d) effect an Acquisition or to liquidate, dissolve or wind up;

then, in connection with each such event, the Company shall give Holder notice thereof at the same time and in the same manner as given to holders of the outstanding shares of the Class.

SECTION 4. REPRESENTATIONS AND WARRANTIES OF THE HOLDER.

The Holder represents and warrants to the Company as follows:

4.4 Accredited Investor Status. Holder is an “accredited investor” within the meaning of Regulation D promulgated under the Act.

SECTION 5. MISCELLANEOUS.

5.1 Term; Automatic Cashless Exercise Upon Expiration.

5.2 Legends. Each certificate evidencing Shares shall be imprinted with a legend in substantially the following form:

[Holder]

c/o Blue Owl Capital Corporation

399 Park Avenue, 37th Floor

New York, NY 10022

Telephone:

Email address:

with a copy (which shall not constitute notice) to:

Cooley LLP

Attn: Michael Tollini

1299 Pennsylvania Avenue, NW, Suite 700

Washington, DC 20004-2400

Email: mtollini@cooley.com

Notice to the Company shall be addressed as follows until Holder receives notice of a change in address:

XOMA Corporation

Attn: Chief Financial Officer

2200 Powell Street, Suite 310

Emeryville, CA 94608

Telephone:

Email:

With a copy (which shall not constitute notice) to:

Gibson, Dunn & Crutcher LLP

Attn: Ryan Murr and Branden Berns

555 Mission Street, Suite #3000

San Francisco, CA 94105

Telephone: (415) 393-8373; (415) 393-4631

Email: rmurr@gibsondunn.com; bberns@gibsondunn.com

5.9 Governing Law. This Warrant shall be governed by and construed in accordance with the laws of the State of New York, without giving effect to its principles regarding conflicts of law.

5.10 Headings. The headings in this Warrant are for purposes of reference only and shall not limit or otherwise affect the meaning of any provision of this Warrant.

[Remainder of page left blank intentionally]

[Signature page follows]

IN WITNESS WHEREOF, the parties have caused this Warrant to Purchase Stock to be executed by their duly authorized representatives effective as of the Issue Date written above.


“COMPANY”

XOMA CORPORATION

By:
Name:		Thomas Burns
Title:		Chief Financial Officer

“HOLDER”

[BLUE OWL CAPITAL CORPORATION]

By:
Name:
Title:

APPENDIX 1

NOTICE OF EXERCISE

[ ] check in the amount of $________ payable to order of the Company enclosed herewith

[ ] Wire transfer of immediately available funds to the Company’s account

[ ] Cashless Exercise pursuant to Section 1.2 of the Warrant

[ ] Other [Describe] __________________________________________

2. Please issue a certificate or certificates representing the Shares in the name specified below:

__________________________________________

Holder’s Name

__________________________________________

(Address)

3. By its execution below and for the benefit of the Company, Holder hereby restates each of the representations and warranties in Section 4 of the Warrant to Purchase Stock as of the date hereof.

HOLDER:

_______________________________

By:_________________________________

Name:________________________________

Title:_________________________________

(Date):_______________________________

Appendix 1

Schedule 1

Representations and Warranties of the Company

Schedule 1.1

(g) No Default or Event of Default has occurred and is continuing, and no such event will occur upon the making of the Term Loan to be made on the applicable Credit Date.

Schedule 1.1

EX-4.3 4 d669381dex43.htm EX-4.3 EX-4.3

Exhibit 4.3

WARRANT TO PURCHASE STOCK

Warrant No.: [●]

Company: XOMA Corporation, a Delaware corporation

Number of Shares: [●], subject to adjustment

Type/Series of Stock: Common Stock, $0.0075 par value per share

Warrant Price: $50.00 per share, subject to adjustment

Issue Date: December 15, 2023

Expiration Date: December 15, 2033 See also Section 5.1(b).

SECTION 1. EXERCISE.

X = Y(A-B)/A

where:

X = the number of Shares to be issued to the Holder;

Y = the number of Shares with respect to which this Warrant is being exercised (inclusive of the Shares surrendered to the Company in payment of the aggregate Warrant Price);

A = the Fair Market Value (as determined pursuant to Section 1.3 below) of one Share; and

B = the Warrant Price.

1.6 Treatment of Warrant Upon Acquisition of Company.

SECTION 2. ADJUSTMENTS TO THE SHARES AND WARRANT PRICE.

SECTION 3. REPRESENTATIONS AND COVENANTS OF THE COMPANY.

3.1 Representations and Warranties. The Company represents and warrants to, and agrees with, the Holder as follows:

3.2 Notice of Certain Events. If the Company proposes at any time to:

(a) declare any dividend or distribution upon the outstanding shares of the Class, whether in cash, property, stock, or other securities and whether or not a regular cash dividend;

(c) effect any reclassification, exchange, combination, substitution, reorganization or recapitalization of the outstanding shares of the Class; or

(d) effect an Acquisition or to liquidate, dissolve or wind up;

then, in connection with each such event, the Company shall give Holder notice thereof at the same time and in the same manner as given to holders of the outstanding shares of the Class.

SECTION 4. REPRESENTATIONS AND WARRANTIES OF THE HOLDER.

The Holder represents and warrants to the Company as follows:

4.4 Accredited Investor Status. Holder is an “accredited investor” within the meaning of Regulation D promulgated under the Act.

SECTION 5. MISCELLANEOUS.

5.1 Term; Automatic Cashless Exercise Upon Expiration.

5.2 Legends. Each certificate evidencing Shares shall be imprinted with a legend in substantially the following form:

[Holder]

c/o Blue Owl Capital Corporation

399 Park Avenue, 37th Floor

New York, NY 10022

Telephone:

Email address:

with a copy (which shall not constitute notice) to:

Cooley LLP

Attn: Michael Tollini

1299 Pennsylvania Avenue, NW, Suite 700

Washington, DC 20004-2400

Email: mtollini@cooley.com

Notice to the Company shall be addressed as follows until Holder receives notice of a change in address:

XOMA Corporation

Attn: Chief Financial Officer

2200 Powell Street, Suite 310

Emeryville, CA 94608

Telephone:

Email:

With a copy (which shall not constitute notice) to:

Gibson, Dunn & Crutcher LLP

Attn: Ryan Murr and Branden Berns

555 Mission Street, Suite #3000

San Francisco, CA 94105

Telephone: (415) 393-8373; (415) 393-4631

Email: rmurr@gibsondunn.com; bberns@gibsondunn.com

5.9 Governing Law. This Warrant shall be governed by and construed in accordance with the laws of the State of New York, without giving effect to its principles regarding conflicts of law.

5.10 Headings. The headings in this Warrant are for purposes of reference only and shall not limit or otherwise affect the meaning of any provision of this Warrant.

[Remainder of page left blank intentionally]

[Signature page follows]

IN WITNESS WHEREOF, the parties have caused this Warrant to Purchase Stock to be executed by their duly authorized representatives effective as of the Issue Date written above.


“COMPANY”

XOMA CORPORATION

By:
Name:		Thomas Burns
Title:		Chief Financial Officer

“HOLDER”

[BLUE OWL CAPITAL CORPORATION]

By:
Name:
Title:

APPENDIX 1

NOTICE OF EXERCISE

[ ] check in the amount of $________ payable to order of the Company enclosed herewith

[ ] Wire transfer of immediately available funds to the Company’s account

[ ] Cashless Exercise pursuant to Section 1.2 of the Warrant

[ ] Other [Describe] __________________________________________

2. Please issue a certificate or certificates representing the Shares in the name specified below:

__________________________________________

Holder’s Name

__________________________________________

(Address)

3. By its execution below and for the benefit of the Company, Holder hereby restates each of the representations and warranties in Section 4 of the Warrant to Purchase Stock as of the date hereof.

HOLDER:

_______________________________

By:_________________________________

Name:________________________________

Title:_________________________________

(Date):_______________________________

Appendix 1

Schedule 1

Representations and Warranties of the Company

Schedule 1.1

(g) No Default or Event of Default has occurred and is continuing, and no such event will occur upon the making of the Term Loan to be made on the applicable Credit Date.

Schedule 1.1

EX-99.1 5 d669381dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

LOGO

XOMA Raises up to $140 Million in Non-Dilutive, Non-Recourse Financing

from Funds Managed by Blue Owl Capital Backed by VABYSMO^® Royalties

Low-cost financing capitalizes on XOMA’s $14 million acquisition of VABYSMO^® (faricimab) royalties in 2021

Proceeds expected to be used for stock repurchases and additional royalty and milestone acquisitions

Financing from Blue Owl extends XOMA’s capabilities as a leading provider of capital to emerging biotech companies

EMERYVILLE, Calif., December 19, 2023 (GLOBE NEWSWIRE) – XOMA Corporation (Nasdaq: XOMA), the biotech royalty aggregator, today announced it entered into a non-dilutive, non-recourse, royalty-backed loan for up to $140 million of capital with certain funds managed by the credit platform of Blue Owl Capital Inc. (NYSE: OWL).

“The Blue Owl financing provides us with significant non-dilutive capital to drive shareholder value through stock repurchases and additional royalty and milestone acquisitions,” stated Brad Sitko, Chief Investment Officer of XOMA. “This capital infusion comes at an opportune time given the existing state of the biotech funding market, providing us with an opportunity to accelerate the growth of our royalty and milestones portfolio, which currently consists of two marketed products, two programs in or near registration, five assets in Phase 3 development, and over 60 assets in earlier stages of development.”

“Blue Owl’s Life Science efforts are focused on credit, royalty, and equity investments in innovative healthcare and life sciences companies and products. We recognize the value embedded in XOMA’s differentiated royalty and milestone aggregation business strategy. Our long-established relationship with XOMA’s management team gives us confidence that they can continue building a balanced portfolio of current and future royalty-generating assets. This financing establishes a long-term partnership with XOMA, as we help broaden their access to capital for royalty and milestone monetization opportunities,” said Sandip Agarwala, Managing Director at Blue Owl Capital.

Terms of the Agreement

XOMA has drawn down $130 million in principal from Blue Owl and has the option to draw another $10 million should the royalties received from VABYSMO^® (faricimab) sales on or prior to March 15, 2026, exceed a predetermined amount. XOMA is obligated to make semi-annual interest payments at a fixed rate of 9.875% per year until the royalty-backed loan is repaid, at which time VABYSMO^® royalty payments will revert back to XOMA. The loan is repayable over a 15-year period, although XOMA may repay it in full at any time during that period, subject to the terms of the loan. Additionally, XOMA has issued to Blue

Owl warrants to purchase an aggregate of up to 120,000 shares of XOMA’s common stock in three equal tranches with strike prices of $35.00, $42.50, and $50.00 per share, respectively, resulting in implied premiums of 122%, 170%, and 217% to the price of XOMA’s common stock at closing, respectively.

Advisors

Gibson, Dunn & Crutcher LLP served as XOMA’s legal advisor while Blue Owl was advised by Cooley LLP.

About XOMA Corporation

XOMA is a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial and commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. When XOMA acquires the future economics, the seller receives non-dilutive, non-recourse funding they can use to advance their internal drug candidate(s) or for general corporate purposes. The Company has an extensive and growing portfolio with more than 70 assets (asset defined as the right to receive potential future economics associated with the advancement of an underlying therapeutic candidate). For more information about the Company and its portfolio, please visit www.xoma.com.

About Blue Owl Capital Inc.

Blue Owl (NYSE: OWL) is a leading asset manager that is redefining alternatives. With $157 billion in assets under management¹, we invest across three multi-strategy platforms: Credit, GP Strategic Capital, and Real Estate. Anchored by a strong permanent capital base, we provide businesses with private capital solutions to drive long-term growth and offer institutional and individual investors differentiated alternative investment opportunities that aim to deliver strong performance, risk-adjusted returns, and capital preservation. Together with over 650 experienced professionals in more than 10 offices globally, Blue Owl brings the vision and discipline to create the exceptional. To learn more, visit www.blueowl.com.

¹	As of September 30, 2023

Forward-Looking Statements/Explanatory Notes

Certain statements contained in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including statements regarding XOMA driving shareholder value through stock repurchases and royalty acquisitions; the timing and amount of potential commercial payments to XOMA and other developments related to VABYSMO^® (faricimab); the anticipated timings of regulatory filings and approvals related to assets in XOMA’s portfolio; and the ability of XOMA to continue building a balanced portfolio of current and future royalty generating assets. In some cases, you can identify such forward-looking statements by terminology such as “anticipate,” “intend,” “believe,” “estimate,” “plan,” “seek,” “project,” “expect,” “may,” “will”, “would,” “could” or “should,” the negative of these terms or similar expressions. These forward-looking statements are not a guarantee of XOMA’s performance, and you should not place undue reliance on such statements. These statements are based on assumptions that may not prove accurate, and actual results could differ materially from those anticipated due to certain risks inherent in the biotechnology industry, including those related to the fact that our product candidates subject to out-license agreements are still being developed, and our licensees may require substantial funds to continue development which may not be available; we do not know whether there will be, or will continue to be, a

viable market for the products in which we have an ownership or royalty interest; if the therapeutic product candidates to which we have a royalty interest do not receive regulatory approval, our third-party licensees will not be able to market them; and the impact to the global economy as a result of the COVID-19 pandemic. Other potential risks to XOMA meeting these expectations are described in more detail in XOMA’s most recent filing on Form 10-Q and in other filings with the Securities and Exchange Commission. Consider such risks carefully when considering XOMA’s prospects. Any forward-looking statement in this press release represents XOMA’s beliefs and assumptions only as of the date of this press release and should not be relied upon as representing its views as of any subsequent date. XOMA disclaims any obligation to update any forward-looking statement, except as required by applicable law.

EXPLANATORY NOTE: Any references to “portfolio” in this press release refer strictly to milestone and/or royalty rights associated with a basket of drug products in development. Any references to XOMA’s “assets” in this press release refer strictly to milestone and/or royalty rights associated with individual drug products in development.

As of the date of this press release, all assets in XOMA’s milestone and royalty portfolio, except VABYSMO^® (faricimab) and IXINITY^® [coagulation factor IX (recombinant)], are investigational compounds. Efficacy and safety have not been established. There is no guarantee that any of the investigational compounds will become commercially available.

# # #


Investor contact:		Media contact:

Juliane Snowden		Kathy Vincent

XOMA		KV Consulting & Management

+1-646-438-9754		+1-310-403-8951

juliane.snowden@xoma.com		kathy@kathyvincent.com

EX-101.SCH 6 xoma-20231215.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.DEF 7 xoma-20231215_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 8 xoma-20231215_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company Document And Entity Information [Table] Document And Entity Information [Table] Document And Entity Information [Line Items] Document And Entity Information [Line Items] Class of Stock [Axis] Class of Stock [Axis] Class of Stock [Domain] Class of Stock [Domain] Common Stock [Member] Common Stock [Member] Series A Preferred Stock [Member] Series A Preferred Stock [Member] Series B Preferred Stock [Member] Series B Preferred Stock [Member] EX-101.PRE 9 xoma-20231215_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 10 g669381g1219031149496.jpg GRAPHIC begin 644 g669381g1219031149496.jpg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

*9?$%YMCREG$3Y:>ON?>ML+AG6EY&.+Q<Q M5\3>(KGQ#J#2N2MNAQ%%GA1_C699:==:E(\=K"TC(C2-CL ,FGZ=IUSJM]%: M6L9>20X'M[FO;?#WART\/Z?Y$0#RN/WTI'+G_"O5KUX8:"C%:]$>+AL/4QS?#K5_[1\.+;.V9K-O+/^[U7^H_"O+?$FFG2=?O+/&%20E/]T\C M]"*U?A_J_P#9GB:*-VQ#=#R6],G[I_/^=&*@JU&Z]4/!U'0Q%I>C/;*^<]== MI->U!V.6:XD)/_ C7T97SYXKL9-/\3ZA!(#_ *YG4GNK'(/Y&N++6N:2._-4 M^2+\S=^%F/\ A+9,X_X]7Q]=RU[-7SGH6L3:%K%OJ$(R8S\R_P!Y3P1^5>QV M'Q!\/WL2L]V+=R.4F&,'ZT8^C-SYXJZ%EU>G&GR2=F=35#6M6@T32+B_N"-L M2Y5<_>;L/Q-8>H?$3P]8QL4NOM+CHL(SG\>E>5>*_&%YXGG4./*M(SF.$']3 MZFL:&$G.7O*R.C$8VG3C[KNS O;J6^O9[J9MTLSEV/N3FO2?A+H;&6YUJ5/E M4>3"3W/\1_D/Q-,KL Y2WQ O_ 'K^I-7_A/8?:?% M3W3#*VL#,#_M-\H_0FJA^ZPU_(FI^^Q5O/\ (]%^(<1E\"ZDJ_PJC?DZFOG^ M%@D\;$X 8&OHOQG&)?!FK*3C%LS?ES_2OG'O6> ?[MKS-Q'9?Q/]:YUVGOKO+% MYIY6Z]2Q-?0W@SPXGAKP_%;$#[5)^\N&]6/;\.E.JUAZ/+'=A2B\36YY;+^K M'/?%O4A9>&(-/C(4W4H!4?W$Y_GMKQO2[%]2U:TLDSNGF6,8[9.*[+XLZG]L M\5BT5LI9Q!,?[1^8_P Q^50_"K3?MOC))V7*6D32GTS]T?SS^%.C^ZP_-\PK M?O<1R_(]WBC2&%(D&$10JCT KQ#XH^+_ .U]1_LBSDS96K?O&4\22=_P'3\Z M[KXD^+O[ TC[%:R8U"[4A2#S&G=OKV'_ -:O";.TN-1OH;2W0R3S.$11W)K# M!T?^7DC;&UO^74?F534XU&^4!1>7 & !*>*]\T[X8^';;3K>&[LUN+A4'F2 MEB-S=_PJU_PK?PI_T"T_[[/^-:O&T^QDL#5[H^>#J5\1@WMP0?\ IJW^-4S7 MTG_PK;PI_P! I/\ OL_XUX%XIT^/2O%.IV,*E8H;AUC4]ESQ^F*UHXB%5M1, M:^'G22E_ ^[S'K%D3T,I!#?R!HKS\ M8K56>E@I7HKR.W\8KXBUN#H?$L*S1.(;V-<*Y'##T-=317-&I*$^>.AV3I1G#DGJ> :AX,U[3G M(ET^5U'\<8W+^8K':PNUD\LVTH8'&-AKZ7I,#.<#-=TC?#'P_=Z+IM[+?V[07$\H4*XP=JC M@_FQ_*N[HKJJXN52'(T@ZA;*AD:6VD14'\1*G KP4^! M?$F?^032_#SP+>6^M-J6L6CPK;PKL_ACX(GTF6;5M5MS%=?ZN"- MQR@[M^/3\Z]-HHGBI2AR)60H82$9\[=V%%%% M>WFV,'49!.P9_7->YT5K1JNE+F1C6HJK'E9X#X0\*^)]#\3VFH/I%RJ1!\Y4 MCJC#^M%>_45=2NZCO)$TL.J:M%B9'K1D>M5_[/M?^>7_ (\?\:/[/M?^>7_C MQ_QK#0WU+&1ZT9'K5?\ L^U_YY?^/'_&C^S[7_GE_P"/'_&C0-2QD>M+FJW] MGVO_ #R_\>/^-/BM887W1IM;&,Y-&@:C;^Y-GIUU=*H8PPO(%)ZX!./TKSNT M^)NJI86NK:EH BT>XE\L7,4^XCD@G;C/8_E7?ZO&\VB7\4:%Y'MI%55'))4X M%>/V'@?4;32O#]_>6VI7=N+EOMNEMN_=C%O%;ZY<7FGWUDUCJ MED0)X"VX8/0@]Q_B*W-2ENX--N)K&%9[I$+1Q,N1\':9JEQXFUCQ/ MJEF;$WRI%#;.@Z3E*'O'G_\ PLD7.AZ7+862S:M? MW!M_L9?'EL#\Q)QTY7\_:N_3=L7?C=CG'3->>:#X::U^+.M:BVFO':>7OMIB MA";V";BIZ9Y?]:]$IUE!-*']7_R)H.;3<_3[O\SA_&GCV7PQJ=O96M@+QO)\ M^X^8CRTW8!Z?7]*[2WGCNK:*XA8-%*@=&'<$9%>6CP[XGU_6_$6HK#:VD5Z& MLE74(W#&$ 8*8Z= <^M=7\/!J4/A.&QU6TFM[BS=H!YJD;T'*D>HP?4XK=9V614V,VT<^];R-OC5O4 UR'Q.T M^\U/P9+;6-M+<3F9"(XE+' // JUX;\1ZGJMX;6\\-WNFQI%N$T^=I((&WH. M>?TJ.2]-27G^AI[2U5Q?E;\37UNYU"TTJ6;2[(7EVI79 7V!N1GGV&37(>&O M&GB'7M6>V;0(XK:WN#!=2BXR8F&<\8YKOZXOP#IU[87?B1KNUE@6?4I)(C(I M&]23@CU%$''DE=:BJ*7M(V>AVE<,?B$-/_MZ#6+5+:\TSYHHU?(N%/"D9'W+445!RM,==S4;P.P\/W MM[J6AVM[?VRVT\Z[_)5B=JGIGWQBM/(]:*KO96\CEVCRQY)R:R;3=S5)I6)\ MCUHR/6J_]GVO_/+_ ,>/^-']GVO_ #R_\>/^-&@:EC(]:,CUJO\ V?:_\\O_ M !X_XT?V?:_\\O\ QX_XT:!J6,CUHJO_ &?:_P#/+_QXT4:!J6****0PHHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ *HHHH **** /_V0$! end XML 11 R1.htm IDEA: XBRL DOCUMENT v3.23.4

Document and Entity Information

Dec. 15, 2023

Document And Entity Information [Line Items]

Entity Registrant Name XOMA Corp

Entity Incorporation State Country Code DE

Amendment Flag false

Entity Central Index Key 0000791908

Document Type 8-K

Document Period End Date Dec. 15, 2023

Entity File Number 001-39801

Entity Tax Identification Number 52-2154066

Entity Address, Address Line One 2200 Powell Street

Entity Address, Address Line Two Suite 310

Entity Address, City or Town Emeryville

Entity Address, State or Province CA

Entity Address, Postal Zip Code 94608

City Area Code (510)

Local Phone Number 204-7200

Written Communications false

Soliciting Material false

Pre Commencement Tender Offer false

Pre Commencement Issuer Tender Offer false

Entity Emerging Growth Company false

Common Stock [Member]

Document And Entity Information [Line Items]

Security 12b Title Common Stock, $0.0075 par value

Trading Symbol XOMA

Security Exchange Name NASDAQ

Series A Preferred Stock [Member]

Document And Entity Information [Line Items]

Security 12b Title 8.625% Series A Cumulative Perpetual Preferred Stock, par value $0.05 per share

Trading Symbol XOMAP

Security Exchange Name NASDAQ

Series B Preferred Stock [Member]

Document And Entity Information [Line Items]

Security 12b Title Depositary Shares (each representing 1/1000th interest in a share of 8.375% Series B Cumulative Perpetual Preferred Stock, par value $0.05 per share)

Trading Symbol XOMAO

Security Exchange Name NASDAQ

Document and Entity Information	Dec. 15, 2023
Document And Entity Information [Line Items]
Entity Registrant Name	XOMA Corp
Entity Incorporation State Country Code	DE
Amendment Flag	false
Entity Central Index Key	0000791908
Document Type	8-K
Document Period End Date	Dec. 15, 2023
Entity File Number	001-39801
Entity Tax Identification Number	52-2154066
Entity Address, Address Line One	2200 Powell Street
Entity Address, Address Line Two	Suite 310
Entity Address, City or Town	Emeryville
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	94608
City Area Code	(510)
Local Phone Number	204-7200
Written Communications	false
Soliciting Material	false
Pre Commencement Tender Offer	false
Pre Commencement Issuer Tender Offer	false
Entity Emerging Growth Company	false
Common Stock [Member]
Document And Entity Information [Line Items]
Security 12b Title	Common Stock, $0.0075 par value
Trading Symbol	XOMA
Security Exchange Name	NASDAQ
Series A Preferred Stock [Member]
Document And Entity Information [Line Items]
Security 12b Title	8.625% Series A Cumulative Perpetual Preferred Stock, par value $0.05 per share
Trading Symbol	XOMAP
Security Exchange Name	NASDAQ
Series B Preferred Stock [Member]
Document And Entity Information [Line Items]
Security 12b Title	Depositary Shares (each representing 1/1000th interest in a share of 8.375% Series B Cumulative Perpetual Preferred Stock, par value $0.05 per share)
Trading Symbol	XOMAO
Security Exchange Name	NASDAQ

XML 12 d669381d8k_htm.xml IDEA: XBRL DOCUMENT 0000791908 2023-12-15 2023-12-15 0000791908 us-gaap:CommonStockMember 2023-12-15 2023-12-15 0000791908 us-gaap:SeriesAPreferredStockMember 2023-12-15 2023-12-15 0000791908 us-gaap:SeriesBPreferredStockMember 2023-12-15 2023-12-15 XOMA Corp DE false 0000791908 8-K 2023-12-15 001-39801 52-2154066 2200 Powell Street Suite 310 Emeryville CA 94608 (510) 204-7200 false false false false Common Stock, $0.0075 par value XOMA NASDAQ 8.625% Series A Cumulative Perpetual Preferred Stock, par value $0.05 per share XOMAP NASDAQ Depositary Shares (each representing 1/1000th interest in a share of 8.375% Series B Cumulative Perpetual Preferred Stock, par value $0.05 per share) XOMAO NASDAQ false EXCEL 13 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( ! ]DU<'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " 0/9-7^C#Y0.\ K @ $0 &1O8U!R;W!S+V-O&ULS9+/ M3L,P#(=?!>7>NDD1@JCK91,GD)"8!.(6)=X6K?FCQ*C=V].6K1."!^ 8^Y?/ MGR4W.DH=$KZD$#&1Q7PSN,YGJ>.*'8BB!,CZ@$[EFC MVB.(JKH#AZ2,(@43L(@+D;6-T5(G5!32&6_T@H^?J9MA1@-VZ-!3!EYR8.TT M,9Z&KH$K8((1)I>_"V@6XES]$SMW@)V30[9+JN_[LJ_GW+@#A_?GI]=YW<+Z M3,IK'']E*^D4<<4ND]_J]6;[R%I1B;K@HN /6R[D;27%_&UL[5I;<]HX%'[OK]!X9_9M"\8V@;:T$W-I=MNTF83M M3A^%$5B-;'EDD81_OTV23;J;/ 0LZ?O.14?GZ#AY\^XN8NB&B)3R M> +]O6N[!3+ MUES@6QHO(];JM-O=5H1I;*$81V1@?5XL:$#05%%:;U\@M.4?,_@5RU2-9:,! M$U=!)KF(M/+Y;,7\VMX^9<_I.ATR@6XP&U@@?\YOI^1.6HCA5,+$P&IG/U9K MQ]'22(""R7V4!;I)]J/3%0@R#3LZG5C.=GSVQ.V?C,K:=#1M&N#C\7@XMLO2 MBW A(5M>5 TR M6'!VULS2 Y9>*?IUE!K9';O=05SP6.XYB1'^QL4$UFG2&98T1G*=D 4. #?$ MT4Q0?*]!MHK@PI+27)#6SRFU4!H(FLB!]4>"(<7K;YH] M5Z%82=J$^!!&&N*<<^9ST6S[!Z5&T?95O-RCEU@5 9<8WS2J-2S%UGB5P/&M MG#P=$Q+-E L&08:7)"82J3E^34@3_BNEVOZKR2.FJW"$2M"/F(9 M-AIRM1:!MG&IA&!:$L;1>$[2M!'\6:PUDSY@R.S-D77.UI$.$9)>-T(^8LZ+ MD!&_'H8X2IKMHG%8!/V>7L-)P>B"RV;]N'Z&U3-L+([W1]072N0/)J<_Z3(T M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+ M.7\N?<^E[[GT/:'2MSAD6R4)RU3393>* M$IY"&V[I4_5*E=?EK[DHN#Q;Y.FOH70^+,_Y/%_GM,T+,T.WF)&Y M"M-2D&_#^>G%>!KB.=D$N7V85VWGV-'1^^?!4;"C[SR6'<>(\J(A[J&&F,_# M0X=Y>U^89Y7&4#04;6RL)"Q&MV"XU_$L%.!D8"V@!X.O40+R4E5@,5O& RN0 MHGQ,C$7H<.>77%_CT9+CVZ9EM6ZO*7<9;2)2.<)IF!-GJ\K>9;'!51W/55OR ML+YJ/;053L_^6:W(GPP13A8+$DACE!>F2J+S&5.^YRM)Q%4XOT4SMA*7&+SC MYL=Q3E.X$G:V#P(RN;LYJ7IE,6>F\M\M# DL6XA9$N)-7>W5YYNTB42%(JP# 4A M%W+C[^^3:G>,U_HL@6V$5#)DU1?*0XG!/3-R0]A4)?.NVB8+A=OB5,V[&KXF M8$O#>FZ=+2?_VU[4/;07/4;SHYG@'K.' MYA,L0Z1^P7V*BH 1JV*^NJ]/^26<.[1[\8$@F_S6VZ3VW> ,?-2K6J5D*Q$_ M2P=\'Y(&8XQ;]#1?CQ1BK::QK<;:,0QY@%CS#*%F.-^'19H:,]6+K#F-"F]! MU4#E/]O4#6CV#30,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04 M" 0/9-7H(XGPF8% "\&0 & 'AL+W=O+Q(Y+W'%(^74GU22\Y-^0Q2W-]UEH:4[QNMW6\Y!G3 M)[+@.7PRERIC!D[5HJT+Q5E2-*S\]: M8_KZ/.K;!M45?PB^TCO'Q-[*O92?[,EE6RL!(.7!S[A:6J5@..? MK6BK_D[;)2&YEM&P-!)O+-*WO<=L1.@T&PIT&X;1!6W)LOJB@OF&&C M4R571-FK05+=:M08XD=M1F1D%GPIH9T87,BZADPUA>4+>Y$:8-;G,-Z,- MO7;:-O E]M)VO!4\WPB&^P1Y?$)H]XB$01A]WKP-;#5@6 .&E5[D QPW I*/ M[Z$!N30\TW\WT6[4.\WJ=LZ_U@6+^5D+)K7FZH&W1C]^1WO!SPA[5+-'F/IH MBWO+%T(;Q> FKEG&FRAQG3]OKL9D(E6!,'5JILXA3)=Y#'I2;3IQ9ICA\ UE M;M0:7I-&2%SXX@U"UZWINJC(&(8ZJ8;[;C5'[Y!>F@") M8BGT5L(?R3N^;B+"E0+XZP_I,!@@6/T:JX_W\5,QW*V+QB'"FP^.WR$0@QIB MC].05/K,8UFC#0X;MK4@YN2ZS>ZZ:H'"-(*#'T7 0 M4(2'!LY>@T.([M@CN4R@T\1R&QR'M=H)>#R/<"0!Z".$X2< M]='3 :E\]29O'%:/9 AK C*5*\A:L!8%V821NB2@J%GCI'P)VE_T&& M;WUP881]*(YJP]Q;[;]5BV<9?R)?+SBMAB;]Q^HSC,W M(*$S_;#SLMLGU/^?B^^"(<1M?,;C4EEF&MZ3.V&^C,(M)"ZR.U9'Y/O@!%;D M75(P11Y86J+SP:5$B)O\G6*)G:*S=78O&PW'(V#W>!B)"XD0]_>ZR]X\QDN6 M+_C>3:='Z'H\NQC_AC&YF AQ=Y^!#7--QK#4X& JBB>'5 ZJ^=RIYW(D'+YL MY: !\]PG#RYV(CPF#JLN MLJI:@TJ#,-%+IK!*BUQJ17B\^"O-(V K;8JAN'R*/+N'@TO-(^0MM6CGD1,> M3-NQ.O]?I89K/G>NNI"*7C:DHI<(J<59 MO"2*5\QYM:"E;1H$ 2R!1 XK6ZX-'!"V*2XBYV1P$O5=O9Y_;;UBNY;(16/T MM='H$; %>X.AN&R,OE4V>H3V%VQ[YUF\_5WCBMFUJR8IGX-2<-*':: V/Q5L M3HPLJL?S]](8F56'2\Y@ 6XO@,_G4IJG$_O$O_[!9O0O4$L#!!0 ( ! ] MDU>?H!OPL0( .(, - >&PO9 MKEMWDOSAR+DCO9*ZW="C<\W[)&D/1ZY8^\XT7'ND,E8QYU5;)VUC.2M;<%(R M6=[<9(EB0M-BK3MUIUQ+#J;3;D-O:%*L*Z//EI0&@U_*%">/3&[HEDFQMV)8 MRY20IV!>@N%@I+'$>2I\0Q=@:9\"O @:L!SC**&-!6,2,H3O_;C\&3!IK5>% ME#/!)0V&8MTPY[C5=UX9%@_&%Q 9Y=VI\0QKRTZ+Y2T].PP_/LG>V)+;.'36-/+T08I:*Q[V_LL)BS6;_,C16/'DL\&D'+R!6TH>N77B<&GY M85FSX[V;IJFO<,[+?Y#SGZUSS36W3%Z2]J/_-U?Y+8R3\?1<'-&K SI;"5R$ M&_H5[E=YYD#VG9!.Z%$[BK+D^L4Y]>$=V_L+_"J^7U_RBG72[69P0\_R%UZ* M3N7SJGNHR[CJ+'^&^VB1S;>PSR5TR7M>;D?5UOM!)%[P6<<'')XC=\,31S"? M@,41P+ \& /,)WAA>?ZG_:S0_00,X[:*(BO49X7Z!*\8LAT^6)ZX3^Z?^$[S M/$VS#*OH=AMEL,7JEF7P%X^&<0,/+ ]D>ENM\6[C$_+Z'& ]?6U"L)WBDXCM M%*\U(/&Z@4>>Q[N-Y0$/K O8[$#^>!Z8J;A/FD)7,6[8"<:1/,<0F,7XC&89 M4IT,/O'^8* \^>Q\ETWLJ.?]74_P$ M4$L#!!0 ( ! ]DU>7BKL

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end XML 14 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 15 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 16 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.4 html 4 23 1 false 3 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.xoma.com//20231215/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d669381d8k.htm xoma-20231215.xsd xoma-20231215_def.xml xoma-20231215_lab.xml xoma-20231215_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 19 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "d669381d8k.htm": { "nsprefix": "xoma", "nsuri": "http://www.xoma.com/20231215", "dts": { "inline": { "local": [ "d669381d8k.htm" ] }, "schema": { "local": [ "xoma-20231215.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/naics/2023/naics-2023.xsd" ] }, "definitionLink": { "local": [ "xoma-20231215_def.xml" ] }, "labelLink": { "local": [ "xoma-20231215_lab.xml" ] }, "presentationLink": { "local": [ "xoma-20231215_pre.xml" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 1, "axisCustom": 0, "memberStandard": 3, "memberCustom": 0, "hidden": { "total": 4, "http://xbrl.sec.gov/dei/2023": 4 }, "contextCount": 4, "entityCount": 1, "segmentCount": 3, "elementCount": 31, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 29 }, "report": { "R1": { "role": "http://www.xoma.com//20231215/taxonomy/role/DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "duration_2023-12-15_to_2023-12-15", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d669381d8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "duration_2023-12-15_to_2023-12-15", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d669381d8k.htm", "first": true, "unique": true } } }, "tag": { "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://www.xoma.com//20231215/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "terseLabel": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://www.xoma.com//20231215/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementClassOfStockAxis", "presentation": [ "http://www.xoma.com//20231215/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]", "terseLabel": "Class of Stock [Axis]" } } }, "auth_ref": [] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockMember", "presentation": [ "http://www.xoma.com//20231215/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Common Stock [Member]", "terseLabel": "Common Stock [Member]" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.xoma.com//20231215/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.xoma.com//20231215/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.xoma.com//20231215/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.xoma.com//20231215/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.xoma.com//20231215/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "terseLabel": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_SeriesBPreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SeriesBPreferredStockMember", "presentation": [ "http://www.xoma.com//20231215/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Series B Preferred Stock [Member]", "terseLabel": "Series B Preferred Stock [Member]" } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.xoma.com//20231215/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "terseLabel": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.xoma.com//20231215/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://www.xoma.com//20231215/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "xoma_DocumentAndEntityInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.xoma.com/20231215", "localname": "DocumentAndEntityInformationLineItems", "presentation": [ "http://www.xoma.com//20231215/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document And Entity Information [Line Items]", "terseLabel": "Document And Entity Information [Line Items]" } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.xoma.com//20231215/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security 12b Title", "terseLabel": "Security 12b Title", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.xoma.com//20231215/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "terseLabel": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://www.xoma.com//20231215/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://www.xoma.com//20231215/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "terseLabel": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.xoma.com//20231215/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.xoma.com//20231215/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.xoma.com//20231215/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.xoma.com//20231215/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "terseLabel": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "xoma_DocumentAndEntityInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://www.xoma.com/20231215", "localname": "DocumentAndEntityInformationTable", "presentation": [ "http://www.xoma.com//20231215/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document And Entity Information [Table]", "terseLabel": "Document And Entity Information [Table]" } } }, "auth_ref": [] }, "us-gaap_SeriesAPreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SeriesAPreferredStockMember", "presentation": [ "http://www.xoma.com//20231215/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Series A Preferred Stock [Member]", "terseLabel": "Series A Preferred Stock [Member]" } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.xoma.com//20231215/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "terseLabel": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.xoma.com//20231215/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "terseLabel": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.xoma.com//20231215/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockDomain", "presentation": [ "http://www.xoma.com//20231215/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Domain]", "terseLabel": "Class of Stock [Domain]" } } }, "auth_ref": [] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.xoma.com//20231215/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "terseLabel": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.xoma.com//20231215/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "terseLabel": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 20 0001193125-23-298155-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-23-298155-xbrl.zip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end